Pfizer Inc.는 미국 및 해외에서 바이오 의약품을 발견, 개발, 제조, 마케팅, 유통, 판매합니다. 이 회사는 Biopharma, PC1, Pfizer Ignite의 세 가지 사업 부문으로 운영됩니다. 주요 제품으로는 Eliquis 브랜드의 심혈관 대사 질환 제품, Nurtec ODT/Vydura 및 Zavzpret 브랜드의 편두통 제품, Prevnar 계열, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, Trumenba 브랜드의 백신, COVID-19 치료제 Paxlovid 등이 있습니다.
또한, Pfizer Inc.는 Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, Velsipity와 같은 염증 및 면역학 제품, Vyndaqel 계열, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi 브랜드의 희귀 질환 제품, Zavicefta, Octagam, Panzyga 브랜드의 항감염 및 면역글로불린 의약품을 제공합니다. 암 치료를 위한 Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, Talzenna 브랜드의 항암제와 Inflectra 브랜드의 바이오시밀러, Retacrit, Ruxience, Zirabev, Trazimera, Nivestym 등의 항암 바이오시밀러, Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, Bicillin 등의 무균 주사제도 판매합니다. 이 회사는 Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, BioNTech SE와 협력 계약을 맺고 있으며, Boltz, PBC와는 생체 분자 AI 기반 모델 개발 및 배포를 위한 전략적 협력을 진행하고 있습니다.
영어 원문 보기
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
